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Overactive Bladder (OAB) refers to the condi-
tion where the patient consistently and frequently
needs to urinate with or without urinary inconti-
nence that has no correlations to urinary tract infec-
tion or other diseases (1). As such, the main reason
patients seek treatment for OAB is the fact that their
lifestyle becomes impacted significantly, especially
concerning their mental health, sexuality, physical,
social, and emotional wellbeing (2). Besides, OAB
can touch a significant part of the patientís life,
increasing its severity and need for treatment of the
disease. 
Over the years, antimuscarinic medications
have been used as the primary treatment option for
OAB, and it mainly focuses on mitigating its symp-
toms. The use of antimuscarinic medications as a
second-line treatment was supported by the
Canadian Urological Association and European
Association of Urology (3, 4). In addition to this, the
beta-3-adrenoceptor agonist, mirabegron, has also
been applied to treat OAB and is issued as a phar-
macotherapy treatment for the disease. Nonetheless,
healthcare providers need to conduct extensive tests,
especially for proper diagnosis, possible contraindi-
cations, and adverse event profiles, to ensure that
their diagnosis is correct and they select the best
treatment for OAB per patient. Because a wide vari-
ety of comorbidities may produce or worsen OAB
symptoms, diagnostic testing depends on the clinical
scenario and often includes urine analysis, urine cul-
ture, voiding diary, specific questionnaires, blad-
der/renal ultrasound, cystoscopy, different imaging
techniques (e.g., computed tomography, magnetic
resonance imaging), or even urodynamic (pressure-
flow) study (3). The approach enhances the patient-
centered care model while dealing with OAB, but
overall the medications applied for the disease are
currently well tested, with documented adverse
event profiles and contraindications. 
However, a review of publications shows that
there is limited research concerning the period OAB
should be managed pharmacologically and the time
to affect the medications utilized to treat the disease.
Such data is crucial for the effective treatment of
OAB and ensures that doctors and patients can
improve their efficiency and performance in manag-
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ing the condition. Also, it is known that OAB treat-
ment compliance is an issue in routine clinical prac-
tice, thus, providing the above mentioned missing
data would assist in improving the situation and
boost patient conformity (5). Further, patient educa-
tion is an essential principle in OAB and empowers
patients to engage and participate in their treatment
(3). As such, the research concentrates on providing
data related to the period OAB should be managed
pharmacologically, and the time to effect of the
medication. The data will support physicians who
care for OAB patients in their daily practice. 
MATERIALS AND METHODS 
The study utilized the Web of Science databas-
es, MEDLINE, Cochrane Library, and PubMed
Central to find and collect the highest number of
data. The search was guided by reference checks and
multiple keywords to ensure that the data was gath-
ered objectively to minimize the risk of omission of
essential studies. After that, the gather publications
were reviewed manually, and the most related ones
had their references checked to find other correlated
publications that would be important for the study.
Besides, the study chose to view currently available
meta-analyses and systematic reviews that focused
on pharmacotherapy of OAB to increase the data
availability and validity of the research (5-14). 
RESULTS
The onset of medication efficacy
The review of the publications found that data
related to the time-to-effect of medications for
OAB was minimal. The study identified that publi-
cations failed to identify and include clinical or sta-
tistical time data regarding the period when the
OAB medications had made a significant impact
on the disease symptoms. In the vast majority of
trials, time-to-effect has not been considered as a
primary or even secondary outcome. In addition, it
was realized that the efficacy endpoints for most of
the research protocols were assessed from just six
to twelve weeks from the time they started treating
the OAB. 
Antimuscarinics
According to Khullar et al., the darifenacin
made improvements to the patientís OAB symptoms
at 6 to 8 days from the initial time treatment begun
(15). Khullar et al. realized these findings in their
pooled analysis of efficacy and safety for the darife-
nacin while analyzing the time-to-effect of the med-
ication in a randomized to the drug or placebo inves-
tigation that had 1059 participants. 
Similarly, a Canadian group sought to find the
time-to-effect of medication for OAB (16). The
Canadian group used fesoterodine 4 mg compared to
their placebo group and gathered 1013 participants
with OAB. The investigators found that fesoterodine
4 mg made significant enhancement of the diseaseís
symptoms concerning episodes of frequency,
urgency, and urgency urinary incontinence, than the
placebo approach after seven days of treatment. 
Zinner et al. investigated the time-to-effect of
OAB medications as done by the Canadian group,
and Khullar et al. (17). Zinner et al., however,
applied trospium chloride for the treatment approach
for people suffering from OAB. Zinner et al. com-
pared the drug to their placebo group and noted sig-
nificant improvements. Zinner et al. discovered that
in the daytime frequency, average volume per void,
and average urge severity, the trospium chloride led
to an initial seven-day improvement compared to the
placebo approach. Also, the authors realized that the
improvements to the endpoints were sustainable
throughout the treatment period. 
Sussman et al. analyzed the micturition fre-
quency, urgency, and urge urinary incontinence end-
points (18). Sussman et al. utilized a tolterodine
extended-release form. The authors used a post hoc
analysis method and found that in all the assessed
endpoints, the drug significantly improved frequen-
cy, urgency, and incontinence. Sussman et al. iden-
tified that the tolterodineís time-to-effect was five
days and continued to increase into the next two
days. Nonetheless, there some weaknesses in
Sussman et al. approach as it failed to investigate
efficacy before the fifth day, and there was no
placebo control group. 
Solifenacin was also analyzed in terms of the
time-to-effect for OAB (19). The dosage was
applied increasingly to identify when a significant
impact where realized. The research also applied a
randomized methodology with a placebo-controlled
group and a double-blind effectiveness test.
Solifenacinís time-to-effect was shown to be on the
third day when 5 mg of solifenacin was used per
day. 
Our study found that there was a research gap
concerning the time-to-effect of oxybutynin and
propiverine medications (5).
Beta-3 adrenergic receptor agonist
The time-to-effect of mirabegron was not
effectively analyzed in any publications, and this
needed to be addressed. The earliest beneficial
The pharmacotherapy time-to-effect of overactive bladder medications... 413
impact of mirabegron was, however, identified to
occur one week after the treatment begun in a sec-
ond phase study (20). In addition, time to effect of
the drug at 25 mg and 50 mg dosage was identified
to significantly occur in four weeks compared to the
placebo group. The medication showed significant
improvement in frequency, mean volume per mic-
turition, and incontinence. 
Table 1 summarizes available data regarding
the onset of treatment efficacy.
Pharmacotherapy duration
The study found that there was extensive
research on clinical studies relating to OAB phar-
macotherapy, yet there were few publications on
treatment durations concerning the disease. 
One-third of the OAB cases stated that the
main reason for treatment for OAB was stopped
because of the resolution of its bothersome symp-
toms (21-25). Besides, research also specified that
other causes of OAB treatment termination were
associated with adverse effects and failed prospec-
tive medical results. The study found that scholars
and other stakeholders have not identified the best
efficacy duration for OAB as the available data
shows that in most randomized clinical trials it has
been assessed to be between 2 weeks and twelve
months, which is highly ambiguous (5-14). As such,
it could be hypothesized that some research could
underrate the drug effectiveness with short periods
of drug administration (26-28), while the length of
medication in other research could be longer than
needed (29, 30). Added to these challenges is the
fact that there is no standardized definition of refrac-
tory OAB, which means that there are variations in
the initial treatment periods for OAB with other
medications or treatment modalities (31). Also,
there is no consensus on when OAB pharmacother-
apy should be ceased and the period when therapeu-
tic efficacy is sustained after the medication has
stopped. 
Antimuscarinics
In another research, Hsiao et al. analyzed 164
participants issued with 4 mg of tolterodine or 5 mg
of solifenacin prolonged capsule release medication
for their OAB (32). Hsiao et al. observed the
patientís progress for an average follow up of 1
month during a six-month space to determine the
duration of needed treatment. The authors realized
that for the anti-muscarinic administration, the med-
ication period should be a minimum of 3 months. 
Choo et al. took a different approach and assessed
the effects of drug cessation (33). Choo et al. evalu-
ated 68 participants with OAB and focused on the
efficacy of the treatment and the duration it took for
the medication to initiate symptom reduction. Choo
et al. measured changes in the participants that had
been issued 20 mg of propiverine hydrochloride
administered daily and terminated after three-month
medication. The authors found that after the four
weeksí termination of treatment, there was a 35.3%
retreatment rate recorded and attributed this to the
increasing severity of the symptoms. In the retreat-
ment group, older participants had higher scores for
severe urgencies needed for the further treatment
group. Under the urodynamic study, 23 participants
showed detrusor overactivity and had higher rates of
having the OAB symptoms reoccur after their treat-
ment was stopped, but Choo et al. identified that the
correlation was insignificant. As such, Choo et al.
found that three months of 20 mg of propiverine
hydrochloride treatment was useful for OAB, but
once it was stopped, the symptoms had a higher
probability of reoccurring after one month. 
Khullar et al. supported Choo et al. findings on
the cease period for OAB and its later effects on the
patients (34). The British group analyzed 251 par-
ticipants that received fesoterodine, four and eight
mg, and flexible dosage. The authors found that the
symptoms of OAB reduced effectively after 12
weeks of the medication. However, the scholars also
noted that the symptoms of OAB reoccurred after
four weeks when its treatment was stopped. In addi-
tion, 61% of the patients experienced reduced
health-related quality of life, increased micturition
frequency, and severity of bladder-related problems.
The British group then analyzed the escalation of
treatment at the four-week period using a dosage of
4 to 8 mg and found that it failed to reduce the rate
at which the symptoms reoccurred. As such, it can
be stated that the positive changes noted by antimus-
carinic drug treatment on reduced OAB symptoms
during a 12-week treatment period are not sustained
after four weeks when the medications are stopped. 
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In another study, tolterodine extended-release
of 4 mg daily dosage was used to treat OAB (21).
The study utilized 108 participants that had the dis-
ease and developed a methodology that had three
separate research groups that received the treatment
at different intervals. The participants received their
treatments for the OAB but ceased after a 1-, 3- or
6-months difference for each of the three groups.
Later, they were reassessed after three months to
determine the reoccurrence rate and significance of
the OAB symptoms. The results showed that 65%
of the participants needed further treatment, and
62% had a relapse of urgency, frequency, inconti-
nence, and other symptoms. In addition, the study
realized that the longer the duration of treatment,
six months, there is still little improvement in the
prevention of symptom relapse. The study, howev-
er, argued that with keen consultations with the
patients about symptom relapse and retreatment,
stopping medication was possible for those with
improved symptoms status. The research also rec-
ommended practical patient-centered care
approaches that analyze the patientís quality of life,
especially those who are more likely to suffer from
symptom relapse. 
Kim et al. analyzed 371 participants that took
antimuscarinic medication for a minimum of 12
weeks and had their symptoms subsided (35). The
study stopped the treatment and viewed for symp-
tom relapse for 1, 3, 6, and 12 months. One hundred
seventy seven patients did not show recurrence at 6
months. Among this group, 41 participants agreed
for further follow-up and just 4 patients of them
(9.7%) showed recurrence at 12 months; the other
patients continued to be symptom-free up to the 12
months. Besides, the study showed that patients with
concomitant urinary incontinence had a higher
chance of reoccurrence.
Another study in Japan enrolled 73 participants
using solifenacin 5 mg administered daily for three
years (25). The research found that 25% of them
needed retreatment two times after ceasing the med-
ication in ten months.
Yokoyama et al. compared patterns of treat-
ment cessation of two different anticholinergics and
showed that pharmacotherapy duration may fluctu-
ate between various OAB medications (29). The
authors prospectively randomized 109 OAB partici-
pants that had been issued 5 mg of solifenacin once
daily or 0.1 mg imidafenacin twice daily with a
twelve-month treatment plan. Twenty five percent
of patients who canceled medicating with imidafe-
nacin due to improvement required retreatment
within 12 months compared to 53.8% of patients
treated with solifenacin who also required drug
reinitiation during the same time span.
A study in the USA, detailed that 34.6% of
their patients, 103,250, needed retreatments after
two years, 24.1% at one year (36). Also, 65.6% of
the patients used their index anticholinergic agent,
while the rest applied different approaches. The
USA study utilized information from the IMS
LifeLink Health Plan Claims Database. 
Beta-3 adrenergic receptor agonist
Khrut et al. assessed the viability of ceasing
mirabegron treatment after symptoms had decreased
in OAB patients (37). Patients with an Urgency
Bother-Visual Analog Scale score of 50% or less
were counseled to stop mirabegron treatment at the
18-month visit. The authors showed that 26.8 per-
cent of the patients included stopped medicating
with mirabegron without beginning it again at twen-
ty-one months before the following check-up
appointment.
Physician perspective
A Canadian group sought to investigate the
practices utilized by urologists and gynecologists
regarding the treatment of OAB (38). In the survey,
the study found that 52% versus 45% of urologists,
and gynecologists stated that its treatment should be
time defined rather than lifelong. Also, urologists
preferred limited treatment periods than gynecolo-
gists and were more likely to start medication with a
higher dose. 41% of physicians preferred a six-
month treatment period for OAB, and 25% issued
one-year medication time for the same disease. 
DISCUSSION
The study conducted was the first to analyze
the time-to-effect of medication and duration of
treatment for OAB. As such, doctors and patients
cannot develop practical treatment approaches with-
out this information.
The study found a significant research gap for
antimuscarinics and mirabegron time-to-effect for
OAB through its clinical use had been extensively
researched (5-14). Our research of the available lim-
ited data found that for these drugs, the time-to-
effect was after seven days, but more investigation is
needed to analyze this occurrence, especially in the
first week of medication. Most of the studies that we
analyzed were not designed to measure the time-to-
effect.
Also, the optimal time for OAB treatment and
avoidance of symptom reoccurrence has yet to be
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determined. However, the literature review section
of the study explains that OAB treatment for 6 to 12
months may be effective. Nonetheles, in those with a
higher risk of recurrence (particularly elderly, frail,
with concomitant urinary incontinence, and detrusor
overactivity presented in the urodynamic study)
pharmacotherapy might be prolonged (33, 35). We
can only speculate that it may go up to 18 months.
Also, the patients should be enlightened to follow the
medication procedure strictly throughout the period.
After that, cessation of the treatment can be consid-
ered, but it needs to be individualistic towards the
patients. Patients who are going to stop medications
should be carefully counseled and educated about
symptom relapse and retreatment. Those with a high-
er risk of reoccurrence should be informed that they
have a higher risk of lifetime management. 
The presented approach with personalized
management might not fully comply with the stan-
dardization of treatment. However, treatment stan-
dardization in OAB is a significant issue and sever-
al shared pathways need to be considered. First, dis-
parities have been noted between physiciansí and
patientsí perceptions of the impact of a chronic dis-
ease such as OAB (39). Clinicians may underesti-
mate the extent to which patients are affected by
their symptoms in 25ñ37% of cases. Therefore,
reports of medical outcomes after OAB treatment
should include independent, validated question-
naires, self-administered by patients to avoid inter-
viewer bias (40). Second, there is a significant
impact of the placebo effect on OAB treatment out-
comes (41). Current evidence from randomized tri-
als shows that a positive placebo effect occurs in
individuals treated for OAB. Finally, the reason
being that OAB affects people uniquely, leading to
diverse symptoms and other pathophysiologies. 
The OAB should be identified as a multifac-
eted symptom syndrome that is caused by multiple
pathophysiological features rather than simplifying
it into idiopathic without factual support (42). The
approach ensures that the treatment of OAB is an
individualized lead distinction in the phenotypes of
the disease. Also, this contributes to patient-centered
care approaches that include treatment duration and
time of primary efficacy. 
The knowledge presented by the study would
assist doctors to minimize their errors in developing
medication approaches for their patients with OAB.
As such, the administration of ineffective drugs and
its contribution to symptom relapse may be avoided.
The findings lead to one to hypothesize that infor-
mation regarding the time-to-effect and duration of
medicating OAB may lead to effective drug adher-
ence by the patient. The study also acts as a refer-
ence point for future investigators that wish to focus
on the time-to-effect and duration of OAB medica-
tion as available guidelines, including those by the
Canadian Urological Association and European
Association of Urology, have not described stan-
dards for these serious clinical concerns (3, 4). The
current study recommends to future investigators to
analyze the time-to-effect for the first week when
treatment began to determine when symptom
improvements occur at the earliest period. In addi-
tion, to assist physicians in their treatment plan for
OAB patients, accurate evaluation with adequate
follow-up when termination of care is needed, espe-
cially for people with positive medical results.
CONCLUSION
The time-to-effect of OAB medications should
be expected after seven days of treatment to view
significant changes to the patientís symptoms. Also,
it can be recommended that OAB patients can
receive medication for 6 to 12 months before can-
celing the treatment without expecting recurring
symptoms. However, there must be specific and
patient-centered counseling before the treatment is
stopped. Patients that are at a higher risk of symp-
toms reoccurrence may need lifelong OAB pharma-
cotherapy or a shift in medications. 
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